Blockchain Registration Transaction Record

Aptevo and Niowave Join Forces in Radiopharmaceutical Cancer Fight

Aptevo Therapeutics and Niowave collaborate to develop radiopharmaceutical therapies targeting metastatic cancers. Learn how their combined expertise in multispecific platforms and isotope supply advances targeted oncology treatments.

This collaboration matters because it addresses two critical bottlenecks in radiopharmaceutical therapy: precise tumor targeting and reliable isotope supply. By combining Aptevo's multispecific antibody platforms with Niowave's manufacturing capabilities, the partnership could accelerate the development of safer, more effective cancer treatments that minimize collateral damage. For patients with metastatic cancers, this means potential access to therapies that directly destroy tumors without the severe side effects of traditional approaches. The $17 billion investment in the field underscores the high expectations, and this alliance could help unlock the full potential of radiopharmaceuticals, offering hope for those with high unmet medical needs.